NASDAQ:OPNT Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free OPNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$20.03▼$21.1052-Week Range N/AVolume562,700 shsAverage Volume77,920 shsMarket Capitalization$108.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Opiant Pharmaceuticals alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide OPNT Stock News HeadlinesApril 18, 2024 | investing.comHikma Pharmaceuticals PLC ADR (HKMPY)January 31, 2024 | forbes.comIonis PharmaceuticalsApril 29, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 24, 2023 | msn.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 23, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMarch 3, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioFebruary 22, 2023 | finance.yahoo.comOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%February 7, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCApril 29, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.January 26, 2023 | seekingalpha.comHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)January 19, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseJanuary 14, 2023 | thetimes.co.ukDechra Pharmaceuticals defies cooling pets marketJanuary 13, 2023 | seekingalpha.comOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown InJanuary 7, 2023 | businesswire.comOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...November 22, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNovember 15, 2022 | benzinga.comOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant PharmaceuticalsNovember 15, 2022 | benzinga.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNTNovember 14, 2022 | benzinga.comShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with IndiviorNovember 14, 2022 | benzinga.comOPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to ShareholdersNovember 14, 2022 | nasdaq.comIndivior To Buy Opiant For $145 Mln In CashNovember 14, 2022 | seekingalpha.comOpiant surges 123% as Indivior set to acquire overdose therapy maker for $145MNovember 14, 2022 | marketwatch.comOpiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNTNovember 14, 2022 | finance.yahoo.comIndivior PLC to Acquire Opiant PharmaceuticalsNovember 14, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comNarcan Owner Opiant to Be Acquired by Indivior for $145 MillionNovember 2, 2022 | finance.yahoo.comThe past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitableOctober 27, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022See More Headlines Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPNT CUSIPN/A CIK1108924 Webwww.opiant.com Phone(310) 598-5410Fax917-322-2105Employees37Year Founded2009Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.01 million Net Margins-147.90% Pretax Margin-147.84% Return on Equity-97.03% Return on Assets-59.66% Debt Debt-to-Equity Ratio0.60 Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$47.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.75 Book Value$9.92 per share Price / BookN/AMiscellaneous Outstanding Shares5,270,000Free Float3,865,000Market Cap$108.83 million OptionableNot Optionable Beta0.84 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesRoger CrystalPresident, Chief Executive Officer & DirectorDavid D. O'TooleChief Financial Officer & SecretaryPhil SkolnickChief Scientific OfficerMark Jason H. EllisonChief Development OfficerMatthew R. RuthChief Commercial OfficerKey CompetitorsOptiNoseNASDAQ:OPTNCyteir TherapeuticsNASDAQ:CYTTCartesian TherapeuticsNASDAQ:RNACImmunicNASDAQ:IMUXFibroGenNASDAQ:FGENView All Competitors OPNT Stock Analysis - Frequently Asked Questions How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) issued its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to the consensus estimate of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%. During the same quarter in the prior year, the firm earned $0.15 earnings per share. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR). This page (NASDAQ:OPNT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
